VRDN241220P25000
- 0.00
- 0.000.00%
Viridian Therapeutics Newsroom
This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday
Needham Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $38
Needham Reiterates Buy on Viridian Therapeutics, Maintains $38 Price Target
TD Cowen Initiates Viridian Therapeutics(VRDN.US) With Buy Rating
TD Cowen Initiates Coverage On Viridian Therapeutics With Buy Rating
Viridian Therapeutics: Buy Rating Due to Promising TED Therapy and Market Potential
Viridian Therapeutics, Inc. (VRDN): This Small-Cap Stock Is Ready To Explode
Viridian Therapeutics (VRDN) Pioneering Breakthroughs in Thyroid Eye Disease
Viridian Therapeutics Analyst Ratings
Viridian Therapeutics: Promising FcRn Inhibitor Developments and Strong Buy Recommendation
H.C. Wainwright Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $34
In-Depth Examination Of 11 Analyst Recommendations For Viridian Therapeutics
Jefferies Releases a Buy Rating on Viridian Therapeutics (VRDN)
RBC Capital Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $44
Jefferies Initiates Viridian Therapeutics(VRDN.US) With Buy Rating, Announces Target Price $45
A Quick Look at Today's Ratings for Viridian Therapeutics(VRDN.US), With a Forecast Between $38 to $61
Viridian Therapeutics Price Target Maintained With a $38.00/Share by Needham
Viridian Therapeutics Reports Increased Cash Reserves Amid Losses
Positive Outlook for Viridian Therapeutics Driven by Promising VRDN-008 Data and Strategic Expansion
Viridian Therapeutics Earns Buy Rating on Promising Trial Results and Strong Financial Position